Abstracts tagged "cytokines"

Abstract Number: 297 • 2013 ACR/ARHP Annual Meeting
Plasma Nicotinamide Phosphoribosyltransferase Correlates With Markers Of Inflammation and May Predict Early Therapeutic Response To Low-Dose Methotrexate In Juvenile Idiopathic Arthritis
Ryan S. Funk¹, Leon van Haandel¹, Marcia Chan², Lanny J. Rosenwasser², Andrew Lasky³, Maria F. Ibarra⁴, Mark F. Hoeltzel⁵, S.Q. Ye⁶, J.S. Leeder¹ and Mara L Becker⁷, ¹Clinical Pharmacology and Medical Toxicology, Children's Mercy Hospital, Kansas City, MO, ²Pediatric Immunology Research, Children's Mercy Hospital, Kansas City, MO, ³Pediatrics Rheumatology, Children's Mercy Hospital, Kansas City, MO, ⁴Pediatric Rheumatolgy, Children's Mercy Hospital, Kansas City, MO, ⁵Rheumatology Section, Children's Mercy Hospital, Kansas City, MO, ⁶Medical Genetic Research, Children's Mercy Hospital, Kansas City, MO, ⁷Clinical Pharmacology and Rheumatology, Children's Mercy Hospital, Kansas City, MO
Background/Purpose: Despite a poor understanding of its biochemical role in the inflammatory process, nicotinamide phosphoribosyltransferase (NAMPT) has been implicated in a number of autoimmune…
Abstract Number: 2075 • 2013 ACR/ARHP Annual Meeting
Analysis Of The Associations Between Serum Ferritin and Cytokines In Pulmonary Disease Activity With Polymyositis/Dermatomyositis
Hidenaga Kawasumi, Takahisa Gono, Yasushi Kawaguchi, Yasuhiro Katsumata, Masanori Hanaoka, Sayuri Kataoka, Kae Takagi, Hisae Ichida, Sayumi Baba, Yuko Okamoto, Yuko Ota and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Polymyositis (PM) / dermatomyositis (DM) is occasionally complicated by interstitial lung disease (ILD), and ILD is a prognostic factor in PM/DM. We previously reported…
Abstract Number: 1150 • 2013 ACR/ARHP Annual Meeting
Differential Regulation Of IL-10 and Dusp1 Production By Kinases In The p38 MAPK Pathway
Deepa Hammaker¹, Katharyn Topolewski² and G. S. Firestein³, ¹MC 0656, UCSD School of Medicine, La Jolla, CA, ²UCSD School of Medicine, La Jolla, CA, ³Div of Rheumatology, UCSD School of Medicine, La Jolla, CA
Background/Purpose: MAPK kinases MKK3 and MKK6 regulate p38 function in inflammatory diseases like rheumatoid arthritis (RA). Targeting MKK3 or MKK6 might be superior to traditional…
Abstract Number: 175 • 2013 ACR/ARHP Annual Meeting
Dynamics Of The Inflammatory Response In Rheumatoid Arthritis Patients Following Traumatic Injury: Insights From In Vivo,In Silico, and Single Nucleotide Polymorphism Studies
Rajaie Namas¹, Rami Namas², Harpreet Sagar³, Felix Fernandez-Madrid³, Timothy Billiar² and Yoram Vodovotz⁴, ¹Rheumatology, Wayne State University/ Henry Ford Health System, Detroit, MI, ²Surgery, University of Pittsburgh, Pittsburgh, PA, ³Internal Medicine/Rheumatology, Wayne State University, Detroit, MI, ⁴Surgery, Immunology, Computational and Systems Biology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Both traumatic injury/hemorrhagic shock (T/HS) and rheumatoid arthritis (RA) are inflammatory diseases that are major sources of morbidity worldwide. We hypothesize that RA modifies…
Abstract Number: 1869 • 2013 ACR/ARHP Annual Meeting
Serum Cytokine/Chemokine Profiles Are Useful For Evaluating Pathological Conditions Of Rheumatoid Arthritis and Diagnosing Anti-CCP Antibody-Negative Patients
Hitoshi Uga¹, Takahiro Okazawa¹, Yoshiaki Miyamoto¹, Takehiro Hasegawa¹, Jun Saegusa², Goh Tsuji³, Sho Sendo⁴, Akio Morinobu⁵, Shunichi Kumagai^6,7 and Hirokazu Kurata¹, ¹Sysmex Corporation, Kobe, Japan, ²Department of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan, ³Center for Rheumatic Diseases, Shinko Hospital, Kobe, Japan, ⁴Center of rheumatic diseases, Shinko Hospital, Kobe, Japan, ⁵Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁶Center of rheumatic diseases, Shinko hospital, Kobe, Japan, ⁷Department of Evidence-Based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: The diagnosis of anti-CCP antibody (ACPA) negative rheumatoid arthritis (RA) are known to be difficult and delayed as compared with ACPA-positive RA. This study…
Abstract Number: 953 • 2013 ACR/ARHP Annual Meeting
Baseline Serum Interleukin-34 Levels Predict Radiographic Progression In Rheumatoid Arthritis Patients
Sung Hae Chang^1,2, Byoung Youg Choi³, Hyon Joung Cho⁴, Hye Jin Oh⁵, Eun Ha Kang³, Yeong Wook Song^2,6 and Yun Jong Lee^2,7, ¹Internal Medicine Rheumatology, Seoul National University Bundang Hospital, Seongnam-si, South Korea, ²Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ³Internal Medicine, Rheumatology, Seoul National University Bundang Hospital, Seongnam-si, South Korea, ⁴Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea, ⁵Internal Medicine, Rheumatology, Seoul National University Hospital, Seoul, South Korea, ⁶Internal Medicine,Rheumatology, Seoul National University Hospital, Seoul, South Korea, ⁷Division of Rheumatology, Department of Internal Medicine,Seoul National University Bundang Hospital, Seongnam, South Korea
Background/Purpose: Interleukin-34 (IL-34), a novel cytokine playing a critical role in osteoclastogenesis, recently was reported that its expression increases in the synovial tissue and sera…
Abstract Number: 146 • 2013 ACR/ARHP Annual Meeting
The Arthritis Severity Locus Cia4 Is An Early Regulator of IL-6, IL-1β, and NFκB activators’ Expression in Pristane-Induced Arthritis
Max Brenner^1,2, Teresina Laragione^1,2 and Percio Gulko^1,2, ¹Center for Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ²Molecular Medicine, Hosftra North Shore-LIJ School of Medicine, Manhasset, NY
Background/Purpose: Cia4 is a quantitative trait locus on rat chromosome 7 that regulates disease severity and joint damage in three models of rheumatoid arthritis including…
Abstract Number: 1859 • 2013 ACR/ARHP Annual Meeting
OX40⁺ T Cells and OX40L⁺ B Cells Accumulate In The Inflamed Joints and OX40 Signalling Is Skewed Towards Autoreactivity
Julie Kristine Laustsen¹, Tue Rasmussen², Malene Hvid³ and Bent Deleuran⁴, ¹Department of Medical Biomedicine, Aarhus University, Aarhus N, Denmark, ²Dept of Biomedicine, Aarhus University, Aarhus, Denmark, ³Dept. of Clinical Medicine, Aarhus University, Aarhus, Denmark, ⁴Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by the presence of autoantibodies and autoreactive T cells, leading to synovitis and joint destruction. The…
Abstract Number: 958 • 2013 ACR/ARHP Annual Meeting
Serum Cytokine Changes In Rituximab-Treated Rheumatoid Arthritis Patients
Tamarah D. de Jong¹, Saskia Vosslamber¹, Wilco de Jager², Hennie G. Raterman³, Alexandre E. Voskuyl⁴, Kyra A. Gelderman¹ and Cornelis L. Verweij⁵, ¹Pathology, VU University Medical Center, Amsterdam, Netherlands, ²Pediatric Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁴Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁵Pathology and Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Although rituximab therapy is successful in the majority of rheumatoid arthritis (RA) patients, 30-40% of patients do not respond. The mechanism behind this is…
Abstract Number: 1844 • 2013 ACR/ARHP Annual Meeting
Rheumatoid Arthritis, Sjogren’s Syndrome and Systemic Lupus Erythematosus Patients Have a Distinct Spectrum Of Serum Anticytokine Autoantibodies
Sarthak Gupta^1,2, Ioanna P. Tatouli³, Lindsey B. Rosen², Sarfaraz A. Hasni¹, Richard M. Siegel¹, Steven M. Holland², Haralampos M. Moutsopopoulos³ and Sarah K. Browne², ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ³School of Medicine, National University of Athens, Athens, Greece
Background/Purpose: Anticytokine autoantibodies are pathogenic in many hematologic, pulmonary and infectious diseases. However, the prevalence and significance of anticytokine autoantibodies in rheumatic conditions is poorly…
Abstract Number: 929 • 2013 ACR/ARHP Annual Meeting
Blockade Of TNFα Produced By TSLP-Primed CD1c Myeloid Dendritic Cells Skews T Cell Response To Th2 Activity In Rheumatoid Arthritis Patients
F.M. Moret¹, T.R.D.J. Radstake², J.W.J. Bijlsma¹, F.P.J.G. Lafeber¹ and J.A.G. van Roon³, ¹Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Thymic stromal lymphopoietin (TSLP) is well known for its potent activation of myeloid dendritic cells (mDCs) to induce Th2-mediated immune responses. Additionally, TSLP and…
Abstract Number: 2858 • 2013 ACR/ARHP Annual Meeting
Inhibition Of Chronic Pain By IL4-10 Synerkine Is Superior To IL-4 Or IL-10 Monotherapy: A Novel Strategy To Restrain Pain In Rheumatic Diseases
Niels Eijkelkamp¹, Sarita Hartgring², Cristine Steen-Louws³, Hanneke Willemen⁴, Qiu-Ling Mao-Ying⁵, Cobi Heijnen⁵, Erik Hack⁶, Annemiek Kavelaars⁵ and J.A.G. van Roon⁷, ¹Laboratory of Neuroimmunology and Developmental Origins of Disease (NIDOD), UMC Utrecht, Utrecht, Netherlands, ²Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³UMC Utrecht, Utrecht, Netherlands, ⁴NIDOD, UMC Utrecht, Utrecht, Netherlands, ⁵MD Anderson Cancer Center, Houston, TX, ⁶Immunology, UMC Utrecht, Utrecht, Netherlands, ⁷Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Chronic pain is a major problem in many diseases, including RA and OA, arising from inflammation or structural damage. It is often associated with glial…
Abstract Number: 1845 • 2013 ACR/ARHP Annual Meeting
Soluble Type I Interferon Receptor 2 Is Elevated By Interferon Treatment and In Certain Autoimmune Diseases
Taher Fatakdawala¹, Michael Skawinski¹, Jonathan Ferriera², Tara Stauffer¹ and Thomas Lavoie¹, ¹Product Research & Development and Assay Services, PBL Assay Science, Piscataway, NJ, ²Quality Control, PBL Assay Science, Piscataway, NJ
Background/Purpose: The Type I Interferon (IFN) receptor is a heterodimer of chain 1 (IFNAR1) which is required for signaling, and chain 2 (IFNAR2) which binds…
Abstract Number: 934 • 2013 ACR/ARHP Annual Meeting
Interleukin-12B Is Up-Regulated By Decoy Receptor 3 In Specifically Rheumatoid Synovial Fibroblasts
Koji Fukuda¹, Yasushi Miura^1,2, Toshihisa Maeda¹, Shinya Hayashi³ and Masahiro Kurosaka³, ¹Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan, ³Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: Decoy receptor 3 (DcR3) is a secreted decoy tumor necrosis factor receptor and competitively binds and inhibits the TNF family including Fas-ligand (FasL), LIGHT,…
Abstract Number: 2740 • 2013 ACR/ARHP Annual Meeting
High Efficacy Of Toll-Like Receptor 4 Targeting In Murine and Humanized Models Of Rheumatoid Arthritis In Comparison With IL-1 and TNF Inhibitors
Shahla Abdollahi-Roodsaz¹, Marije I. Koenders², Leo A. Joosten³, Fons A. van de Loo⁴ and Wim B. van den Berg¹, ¹Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ³Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ⁴Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands
Background/Purpose: Increased expression of Toll-like Receptor (TLR) 4 and its endogenous agonists in rheumatoid joints suggest involvement in rheumatoid arthritis (RA). The aim of this…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].